|Articles|February 4, 2016
LabConnect Builds New Biorepository
Advertisement
Expands Services, Offers Absolute Sample Protection
(Seattle, Wash.; Feb. 3, 2016) - LabConnect , a leading provider of highly customized global central laboratory services to biopharmaceutical, medical device and contract research organizations, has built a new biorepository facility to expand services and better meet the evolving needs of the industry.
LabConnect’s new, 5,000-square-foot biorepository in Johnson City, Tenn., features space for ambient, refrigerated, cold (-20C) and ultra-low temperature (-70C to -80C) storage as well as liquid nitrogen vapor phase storage (-190C).
“Proper sample management is essential to both today’s and tomorrow’s clinical trials,” said Eric Hayashi , LabConnect president and CEO. “Researchers depend on the integrity and availability of their stored biospecimens to retest them to verify trends or unexpected results, or for later retrieval to support specific biomarker research.”
With storage capacity for more than 8 million samples, LabConnect ensures the integrity of samples as well as business continuity with fully validated and mapped backup freezers and generators, redundant HVAC systems, whole building and biorepository security systems and a temperature monitoring system for all freezers and refrigerators with a 21 CFR Part 11 compliant audit trail.
“There are many biorepositories, but LabConnect’s facility is truly state-of-the art, using the most advanced technology available to provide the best protection in the industry for biospecimens,” said George Lewis, senior engineering technician at Johnson Controls, which supplies equipment to the Johnson City facility.
Additionally, through its SampleGISTICS™ system, LabConnect tracks sample locations and consolidates data within a centralized database accessible to researchers 24/7.
Newsletter
Stay current in clinical research with Applied Clinical Trials, providing expert insights, regulatory updates, and practical strategies for successful clinical trial design and execution.
Advertisement
Related Articles
- How Sponsors Can Modernize Tools to Support Physicians
September 9th 2025
Advertisement
Advertisement
Trending on Applied Clinical Trials Online
1
ACT Brief Episode 7: Veeva and Merck Trial Efficiency, DCT Barriers, and Glucose Monitoring Strategies
2
Pfizer, BioNTech’s Comirnaty Shows Strong Immune Response in Phase III Trial for COVID-19
3
Beyond the Algorithm: How Human-Centered AI Design Can Drive Clinical Trial Success
4
Summit Therapeutics’ Bispecific Antibody Shows Positive Survival Trend in Non-Small Cell Lung Cancer
5